×
About 10,438 results

ALLMedicine™ Vitamin K Center

Research & Reviews  3,479 results

The Dilemma of Peri-Procedural Warfarin Management: A Narrative Review.
https://doi.org/10.1177/10760296211012093
Clinical and Applied Thrombosis/hemostasis : Official Jou... Eljilany I, El-Bardissy A et. al.

Dec 1st, 2021 - Periprocedural vitamin K antagonist management is a complex process and inherently entails multiple clinical issues. Marked variations have been reported in different aspects of this process. These differences were noted at the clinician and insti...

The influence of excessive consumption of liquorice on phenprocoumon (Marcumar®): a cas...
https://doi.org/10.1177/03000605211049649
The Journal of International Medical Research; Roemer HC, Kunz L et. al.

Nov 27th, 2021 - Here, the case of a 92-year-old female patient, who was diagnosed with atrial fibrillation and treated with phenprocoumon (Marcumar®), is reported. Pre-existing comorbidities were arterial hypertension, coronary heart disease, diabetes mellitus ty...

Clopidogrel or ticagrelor alongside dabigatran in acute coronary syndrome and indicatio...
https://doi.org/10.2217/fca-2021-0085
Future Cardiology; Luijkx J, Winkler P et. al.

Nov 26th, 2021 - The combination of oral anticoagulants with platelet inhibitors has been widely investigated in patients with coronary stenting and concomitant atrial fibrillation. In these patients, default therapy after percutaneous coronary intervention in acu...

Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation a...
https://doi.org/10.1161/JAHA.121.022628
Journal of the American Heart Association; Melgaard L, Overvad TF et. al.

Nov 25th, 2021 - Background Guideline recommendations on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with aortic stenosis are based on studies including a low number of patients with aortic stenosis. The aim...

see more →

Guidelines  13 results

2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Managemen...
https://doi.org/10.1016/j.cjca.2018.08.026
The Canadian Journal of Cardiology; Andrade JG, Verma A et. al.

Nov 9th, 2018 - The Canadian Cardiovascular Society (CCS) Atrial Fibrillation Guidelines Committee provides periodic reviews of new data to produce focused updates that address clinically important advances in atrial fibrillation (AF) management. This 2018 Focuse...

THE USE OF VITAMINS AND MINERALS IN SKELETAL HEALTH: AMERICAN ASSOCIATION OF CLINICAL E...
https://doi.org/10.4158/PS-2018-0050
Endocrine Practice : Official Journal of the American Col... Hurley DL, Binkley N et. al.

Jul 24th, 2018 - 25(OH)D = 25-hydroxyvitamin D; BMD = bone mineral density; CV = cardiovascular; GI = gastrointestinal; IOM = Institute of Medicine; PTH = parathyroid hormone; RCT = randomized controlled trial; αTF = α-tocopherol; ucOC = undercarboxylated osteocal...

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K ...
https://doi.org/10.1093/eurheartj/ehy136
European Heart Journal; Steffel J, Verhamme P et. al.

Mar 22nd, 2018 - The current manuscript is the second update of the original Practical Guide, published in 2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrilla...

Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.
https://doi.org/10.1016/j.chest.2015.11.026
Chest Kearon C, Akl EA et. al.

Feb 13th, 2016 - We update recommendations on 12 topics that were in the 9th edition of these guidelines, and address 3 new topics. We generate strong (Grade 1) and weak (Grade 2) recommendations based on high- (Grade A), moderate- (Grade B), and low- (Grade C) qu...

Patient self-testing and self-management of oral anticoagulation with vitamin K antagon...
https://doi.org/10.1111/bjh.13070
British Journal of Haematology; Jennings I, Kitchen D et. al.

Aug 22nd, 2014 - Patient self-testing and self-management of oral anticoagulation with vitamin K antagonists: guidance from the British Committee for Standards in Haematology.|2014|Jennings I,Kitchen D,Keeling D,Fitzmaurice D,Heneghan C,|administration & dosage,ad...

see more →

Drugs  74 results see all →

Clinicaltrials.gov  157 results

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Wh...
https://clinicaltrials.gov/ct2/show/NCT04249401

Nov 18th, 2021 - Oral anticoagulant (OAC) treatment with either vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) is essential in patients with atrial fibrillation for the prevention of stroke or systemic embolism (SE) a conditio...

Development and Validation of Automated Indicators on the Appropriateness of Oral Anticoagulant Prescriptions
https://clinicaltrials.gov/ct2/show/NCT02898090

Nov 17th, 2021 - The appropriateness of oral anticoagulant prescriptions (Vitamin K Antagonists and Direct Oral Anticoagulants) is a major challenge for improving quality, safety and efficiency of care. The large targeted population, prescription frequency and str...

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
https://clinicaltrials.gov/ct2/show/NCT04794569

Nov 11th, 2021 - The TILE pilot study will investigate the magnitude of difference in effectiveness between LMWH (low molecular weight heparin, tinzaparin) plus DOAC (Direct Oral Anticoagulants, rivaroxaban) vs. DOAC alone to determine the sample size and assess f...

A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Usi...
https://clinicaltrials.gov/ct2/show/NCT04722679

Oct 26th, 2021 - Atrial fibrillation is a heart condition that causes an abnormal and fast heart rate. For people with non-valvular atrial fibrillation (NVAF), this is caused by problems such as high blood pressure and diabetes. NVAF happens more often in elderly ...

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA
https://clinicaltrials.gov/ct2/show/NCT02507856

Oct 13th, 2021 - The multi-center, prospective PRODAST study is investigating patients with non-valvular atrial fibrillation (AF) who experienced an ischemic stroke or a transient ischemic attack (TIA) recently (≤ 1 week) both with and without previous oral antico...

see more →

News  449 results

AGA Clinical Practice Guideline: Managing Coagulation Disorders in Patients With Cirrhosis
https://www.medscape.com/viewarticle/962367

Nov 5th, 2021 - A clinical update from the American Gastroenterological Association focuses on bleeding and thrombosis-related questions in patients with cirrhosis. It provides guidance on test strategies for bleeding risk, preprocedure management of bleeding ris...

AGA Clinical Practice Guideline: Coagulation in cirrhosis
https://www.mdedge.com/internalmedicine/article/248270/hepatology/aga-clinical-practice-guideline-coagulation-cirrhosis
Jim Kling

Nov 4th, 2021 - A clinical update from the American Gastroenterological Association focuses on bleeding and thrombosis-related questions in patients with cirrhosis. It provides guidance on test strategies for bleeding risk, preprocedure management of bleeding ris.

Does Oral Anticoagulant Type Influence the Risk of Dementia?
https://www.medscape.com/viewarticle/961122

Oct 19th, 2021 - Individuals with newly diagnosed atrial fibrillation (AF) receiving direct oral anticoagulants (DOACs) have a lower risk of incident dementia and mild cognitive impairment (MCI) than those receiving vitamin K antagonists (VKAs), a new study publis...

New predictive markers for risk of HCC in cirrhotic chronic hepatitis B
https://www.mdedge.com/fedprac/article/246275/hepatocellular-carcinoma/new-predictive-markers-risk-hcc-cirrhotic-chronic

Sep 18th, 2021 - Key clinical point : Serum Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) and alpha-fetoprotein were significant predictors of hepatocellular carcionoma and death in patients with chronic hepatitis B-related cirrhosis. Major.

Study Describes Bleeding Risk With Anticoagulants for VTE
https://www.medscape.com/viewarticle/958711

Sep 14th, 2021 - A new study may help doctors assess the long-term risk for major bleeding if anticoagulation for unprovoked venous thromboembolisms (VTE) is continued beyond 3-6 months. The meta-analysis of data from 27 studies with 17,202 patients was published ...

see more →

Patient Education  3 results see all →